Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Authors

Ahmed Amro, Marshall University Joan C. Edwards School of MedicineFollow
Kanaan Mansoor, Marshall University Joan C. Edwards School of MedicineFollow
Mohammad Amro, School of Medicine, MUST – Misr University for Science & TechnologyFollow
Amal Sobeih, School of Medicine, Al-Najah UniversityFollow
Obadah Aqtash, Marshall University Joan C. Edwards School of MedicineFollow
Hisham Hirzallah, Marshall University Joan C. Edwards School of MedicineFollow
Alaa Gabi, Marshall University Joan C. Edwards School of MedicineFollow
Madhulika Urella, Marshall University Joan C. Edwards School of MedicineFollow
Waseem Ahmed, Marshall University Joan C. Edwards School of MedicineFollow
Sandra Shenouda, Marshall University Joan C. Edwards School of MedicineFollow
Dr. Rameez Sayyed, MD, Marshall University Joan C. Edwards School of MedicineFollow

Author Credentials

Ahmed Amro MD Kanaan Mansoor MD Mohammad Amro MD Amal Sobeih MD Obadah Aqtash MD Hisham Hirzallah MD Alaa Gabi MD Madhulika Urella MD Waseem Ahmed MD Sandra Shenouda MD Rameez Sayyed MD

Keywords

Prasugrel, inappropriate use, Coronary intervention, DAPT

Disciplines

Cardiology | Critical Care | Medicine and Health Sciences

Abstract

Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.

Recommended Citation

Amro A, Mansoor K, Amro M, et al. Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study. Marshall J Med. 2019; 5(3): 30 DOI: https://doi.org/10.33470/2379-9536.1220.